Ocular Therapeutix (NASDAQ:OCUL) reported Q3 CY2025 results with revenue of $14.54 million, beating analyst estimates by 3.8%. However, sales fell by 5.7% year on year. The company’s non-GAAP loss per share was $0.38, missing analysts’ expectations by 9.6%. Ocular Therapeutix develops sustained-release eye treatments using ELUTYX bioresorbable hydrogel technology. Over the last five years, the company has grown its sales at a rate of 39.5% annually, but recent trends show revenue declining by 1.7% over the past two years. Analysts project a 6.3% revenue growth over the next 12 months. In Q3, the company reported a negative 472% adjusted operating margin.

Read more at Stockstory.org – Bloomberg: Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales